Figure 5 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy

Carboplatin increases CLDN6 expression, accompanied by changes in EMT- and ECM-related genes. A, qPCR data of CLDN6, CD44, and TGFβ1 expression in NIH:OVCAR-3 cells treated with indicated cytotoxic agents for 8 days. Medium-only wells served as the nontreated control. Quantitative data are presented as the mean ± SD (n = 3). P values were determined by two-tailed Student t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. B, qPCR data of CLDN6 and CD44 in COV318, COV362, and H1435 cells treated with carboplatin (blue) or medium only (nontreated, red) for 7 or 8 days. Quantitative data are presented as the mean ± SD (n = 3). P values were determined by two-tailed Student t test. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. C and D, Heatmap of nCounter Analysis System results for NIH:OVCAR-3 cells treated with carboplatin, cisplatin, and doxorubicin. Medium-only wells served as the nontreated control. The heatmap shows differential expression in genes involved in EMT (C) and ECM remodeling and ECM–receptor interaction (D) of each treatment group (n = 3).